Literature DB >> 12502121

Patients with psoriasis prefer solution and foam vehicles: a quantitative assessment of vehicle preference.

Tamara Salam Housman1, Beverly G Mellen, Stephen R Rapp, Alan B Fleischer, Steven R Feldman.   

Abstract

Psoriasis patients' acceptance of the vehicles used in topical therapy contributes to adherence to treatment plans and outcomes, but patient preferences for different vehicles have not been assessed. The purpose of this study was to develop a quantitative measure of patient preferences for different vehicles and to assess these preferences. Focus group sessions were conducted of patients with psoriasis to determine patient perceptions of the advantages and disadvantages of different topical psoriasis therapies. This information was used to derive a vehicle preference measure to assess different topical therapies. Twenty patients with psoriasis sampled different topical psoriasis medications, assessed the effects of the vehicles on quality of life (QOL), and completed the preference measure for each vehicle. The focus group sessions resulted in the development of a 7-item preference measure. The validity of the vehicle preference measure was demonstrated by good correlation with patient expectations of effects on QOL and by test-retest reliability. The foam and solution vehicles were preferred over the cream, gel, and ointment vehicles (P < .01). There was no significant difference between preferences for daytime and nighttime application of vehicles. Although validated measures of adherence to topical therapy are not yet available, the results of this study suggest that the characteristics of solution and foam may favor improved adherence to topical therapy.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12502121

Source DB:  PubMed          Journal:  Cutis        ISSN: 0011-4162


  14 in total

1.  The use of sodium sulfacetamide 10%-sulfur 5% emollient foam in the treatment of acne vulgaris.

Authors:  James Q Del Rosso
Journal:  J Clin Aesthet Dermatol       Date:  2009-08

2.  Physician and Patient Assessment of Triamcinolone Acetonide Spray for Steroid-responsive Dermatoses.

Authors:  Joseph Fowler; Lynn Fowler
Journal:  J Clin Aesthet Dermatol       Date:  2010-05

Review 3.  Relative efficacy and interchangeability ofvarious clobetasol propionate vehicles in the management of steroid-responsive dermatoses.

Authors:  Steven R Feldman
Journal:  Curr Ther Res Clin Exp       Date:  2005-05

4.  In Vitro Evaluation of a Foamable Microemulsion Towards an Improved Topical Delivery of Diclofenac Sodium.

Authors:  Braa Hajjar; Jieyu Zuo; Chulhun Park; Shirzad Azarmi; Daniela Amaral Silva; Nádia Araci Bou-Chacra; Raimar Löbenberg
Journal:  AAPS PharmSciTech       Date:  2022-04-04       Impact factor: 3.246

5.  It is not always about gains: utilities and disutilities associated with treatment features in patients with moderate-to-severe psoriasis.

Authors:  Nasir Umar; Ina Schöllgen; Darcey D Terris
Journal:  Patient Prefer Adherence       Date:  2012-03-15       Impact factor: 2.711

6.  Efficacy of an innovative aerosol foam formulation of fixed combination calcipotriol plus betamethasone dipropionate in patients with psoriasis vulgaris.

Authors:  Catherine Queille-Roussel; Martin Olesen; John Villumsen; Jean-Philippe Lacour
Journal:  Clin Drug Investig       Date:  2015-04       Impact factor: 2.859

7.  Patients with psoriasis have different preferences for topical therapy, highlighting the importance of individualized treatment approaches: randomized phase IIIb PSO-INSIGHTFUL study.

Authors:  C-H Hong; K A Papp; K W Lophaven; P Skallerup; S Philipp
Journal:  J Eur Acad Dermatol Venereol       Date:  2017-09-14       Impact factor: 6.166

8.  Patient Preferences for Topical Psoriasis Treatments are Diverse and Difficult to Predict.

Authors:  Lars Iversen; Henny B Jakobsen
Journal:  Dermatol Ther (Heidelb)       Date:  2016-04-28

9.  Real-life effectiveness of once-daily calcipotriol and betamethasone dipropionate gel vs. ointment formulations in psoriasis vulgaris: final analysis of the 52-week PRO-long study.

Authors:  J Lambert; C W Hol; J Vink
Journal:  J Eur Acad Dermatol Venereol       Date:  2015-09-03       Impact factor: 6.166

10.  A Novel Aerosol Foam Formulation of Calcipotriol and Betamethasone Has No Impact on HPA Axis and Calcium Homeostasis in Patients With Extensive Psoriasis Vulgaris.

Authors:  Victoria Taraska; Raj Tuppal; Martin Olesen; Claus Bang Pedersen; Kim Papp
Journal:  J Cutan Med Surg       Date:  2015-07-29       Impact factor: 2.092

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.